Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company whose news flow reflects its role in life science tools, bioactive reagents, diagnostics, and spatial biology. Company announcements frequently highlight financial results, product launches, collaborations, and participation in healthcare and investor conferences, giving investors and researchers insight into how Bio-Techne is executing its strategy.
Recent press releases include quarterly and annual financial updates, where Bio-Techne reports net sales, segment performance for its Protein Sciences and Diagnostics and Spatial Biology segments, and commentary on market conditions. These earnings communications often discuss organic revenue trends, operating margins, and portfolio decisions such as divestitures of non-core businesses.
Product and technology news from Bio-Techne covers launches of analytical instruments, spatial biology assays, and multiomic workflows. Examples include announcements of next-generation protein analysis systems with multiplexing capabilities, spatial biology platforms that combine RNA and protein detection, and assays that visualize protein-protein interactions within tissue at subcellular resolution. Such updates show how the company is expanding its proteomic analytical tools and spatial biology offerings, which it identifies as growth pillars.
Bio-Techne also issues news about strategic collaborations and licensing agreements. Recent items describe partnerships in AI-enabled protein design, multiomic spatial analysis with academic and industry partners, and initiatives supporting cell and gene therapy manufacturing workflows. In addition, the company regularly announces its participation in major healthcare and investor conferences, where management presents its outlook and strategy.
This TECH news page aggregates these types of updates so readers can follow Bio-Techne’s financial reporting, product innovation, strategic partnerships, and conference activity in one place. Investors, analysts, and scientists can use this feed to monitor developments across the company’s life science tools, diagnostics, and spatial biology businesses.
Bio-Techne Corporation (NASDAQ:TECH) has launched the miRNAscope™ Assay, extending its RNAscope™ platform. This novel assay enables the in situ detection of microRNAs and short oligonucleotide therapeutics with single-cell resolution in intact tissues. The miRNAscope Assay addresses significant limitations of traditional methods like PCR and sequencing, offering heightened specificity, sensitivity, and ease of interpretation. Bio-Techne's commitment to enhancing RNA detection demonstrates its leadership in tissue analysis, providing essential tools for researchers in diagnostics and therapy development.
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on August 4, 2020, at 8:00 a.m. CDT to discuss its fourth quarter 2020 financial results. Interested participants can access the call via dial-in or through a provided webcast link. A recorded rebroadcast will be available from 11:00 a.m. CDT on August 4 until 11:00 p.m. CDT on September 4. Bio-Techne, a leader in high-quality protein and reagent solutions, reported approximately $714 million in net sales in fiscal 2019, employing around 2,300 people globally.